Abstract:
Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.
Abstract translation:提供肝脏疾病的生物标志物及其使用方法。 为了检测肝硬化和肝癌,生物标志物选自SEQ ID NO:1至SEQ ID NO:24的任一氨基酸序列或衍生物或片段或变体或其组合或针对氨基酸序列的抗体 。 然后生物标志物进一步发展为检测试剂盒,通过检测筛选标本中自身抗体或自身抗原的存在,以更高的准确度和灵敏度检测肝脏疾病。
Abstract:
The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90α), and heat-shock protein 90, beta isoform (hsp90β). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.
Abstract:
Some specific autoantigens of MGN are discovered by using the integrated platform. Moreover, according to the specificity between antibodies and antigens, a method for diagnosing MGN are constructed. This diagnostic method is cooperated with ELISA, RIA, immunofluorescence, or other immunochromatography techniques. Finally, a diagnostic kit is provided to implement the method above.
Abstract:
Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Abstract:
Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Abstract:
Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Abstract:
The present invention provides a method for detecting liver fibrotic injury, including fibrosis and/or cirrhosis, by assaying biological samples for differential expression of at least one gene encoding a protein chosen from SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof, wherein differential expression of at least one gene suggests the presence of liver fibrosis or cirrhosis. The invention also provides a kit containing nucleic acid probes or antibodies for detecting liver fibrosis and/or cirrhosis by assaying the differential expression of proteins encoded by SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof.
Abstract translation:本发明提供一种检测肝纤维化损伤(包括纤维化和/或肝硬化)的方法,通过测定生物样品来鉴别至少一种编码选自SEQ ID NO:1-SEQ ID NO:63的蛋白质的基因和人直向同源物 其中至少一个基因的差异表达表明存在肝纤维化或肝硬化。 本发明还提供了一种试剂盒,其包含通过测定由SEQ ID NO:1-SEQ ID NO:63编码的蛋白质的差异表达及其人类直向同源物来检测肝纤维化和/或肝硬化的核酸探针或抗体。
Abstract:
The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90α), and heat-shock protein 90, beta isoform (hsp90β). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.
Abstract:
The present invention provides a method for detecting liver fibrotic injury, including fibrosis and/or cirrhosis, by assaying biological samples for differential expression of at least one gene encoding a protein chosen from SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof, wherein differential expression of at least one gene suggests the presence of liver fibrosis or cirrhosis. The invention also provides a kit containing nucleic acid probes or antibodies for detecting liver fibrosis and/or cirrhosis by assaying the differential expression of proteins encoded by SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof.
Abstract translation:本发明提供一种检测肝纤维化损伤(包括纤维化和/或肝硬化)的方法,通过测定生物样品来鉴别至少一种编码选自SEQ ID NO:1-SEQ ID NO:63的蛋白质的基因和人直向同源物 其中至少一个基因的差异表达表明存在肝纤维化或肝硬化。 本发明还提供了一种试剂盒,其包含通过测定由SEQ ID NO:1-SEQ ID NO:63编码的蛋白质的差异表达及其人类直向同源物来检测肝纤维化和/或肝硬化的核酸探针或抗体。
Abstract:
Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.